Recent Research into the Liver Fibrosis-Pipeline Review, H2 2016

Liver Fibrosis-Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

To access full report with TOC, please visit Liver Fibrosis-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
- The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Fibrosis therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Advinus Therapeutics Ltd Akarna Therapeutics Ltd. Angion Biomedica Corp. Asubio Pharma Co., Ltd. aTyr Pharma, Inc. Beijing Kawin Technology Share-Holding Co., Ltd. BioLineRx, Ltd. Bioneer Corporation BiOrion Technologies B.V. Bird Rock Bio, Inc. Bristol-Myers Squibb Company Cellmid Limited ContraVir Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. Digna Biotech, S.L. Dr. Falk Pharma GmbH Dynavax Technologies Corporation Evotec AG Galectin Therapeutics, Inc. Genfit SA Gilead Sciences, Inc. GNI Group Ltd. HEC Pharm Co., Ltd. Immuron Limited Intercept Pharmaceuticals, Inc. INVENT Pharmaceuticals, Inc. Isarna Therapeutics GmbH KineMed, Inc. LG Life Science LTD. Nitto Denko Corporation Pfizer Inc. Pharmaxis Limited Promedior, Inc. Promethera Biosciences S.A. ProMetic Life Sciences Inc. Ribomic Inc. RXi Pharmaceuticals Corporation Silence Therapeutics Plc TCM Biotech International Corp Vascular Biogenics Ltd. Virobay Inc. XTuit Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###